SHAREHOLDER ALERT: Law Firm Brower Piven Announces Investigation Of Possible Breaches Of Fiduciary Duty By Directors Of ViroPharma Incorporated In Connection With Proposed Buyout
The securities litigation firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty to current shareholders of ViroPharma Incorporated
The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of ViroPharma Incorporated (“ViroPharma” or the “Company”) (NASDAQ: VPHM) and other violations of state law by the board of directors of ViroPharma relating to the proposed buyout of the Company by Shire Plc. The firm’s investigation seeks to determine, among other things, whether the board of directors of ViroPharma breached their fiduciary duties by failing to maximize shareholder value. According to the press release announcing the proposed buyout, ViroPharma shareholders will receive $50.00 per share in cash for each share of ViroPharma common stock they own. If you currently own common stock of ViroPharma and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at email@example.com, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.